A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN

NCT05856760 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Immunoglobulin A Nephropathy

Interventions

DRUG: Sparsentan

Sponsor

Travere Therapeutics, Inc.